Company announcements · 10/16/2026

Cyrano Therapeutics Announces Presentation of Positive Phase 2 FLAVOR Data Demonstrating Statistically Significant Improvement in Smell Function with CYR-064 in Patients with Post-Viral Smell Loss

Cyrano Therapeutics announced the presentation of positive Phase 2 FLAVOR data, demonstrating a statistically significant improvement in smell function with CYR-064 in patients with post-viral smell loss, at the 72nd Annual Meeting of the American Rhinologic Society.